search
Back to results

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic Dermatitis

Primary Purpose

Atopic Dermatitis

Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
AK120
AK120
Placebo
AK120
AK120
AK120
Placebo
AK120
AK120
AK120
Sponsored by
Akeso
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Atopic Dermatitis

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Male or female with age 18 - 75 years (inclusive). Atopic dermatitis (AD) diagnosed at least half an year before screening. Subject with EASI score ≥16, IGA ≥ 3, BSA ≥ 10% at screening and baseline. Subjects with a history of an inadequate response or medically inappropriate use of topical drug treatment within 6 months. Exclusion Criteria: Suffering from other inflammatory diseases that may affect efficacy outcomes (such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, scleroderma, inflammatory myopathy, mixed connective tissue disease, overlap syndrome, etc.). History of exposure to active TB, and/or history or current evidence of TB infection. Positive serology results at Screening for hepatitis B, hepatitis C or HIV. Any history of vernal keratoconjunctivitis (VKC) or atopic keratoconjunctivitis (AKC) within 6 months before the baseline visit. History of clinical parasite infection, recent or planned travel to an area with endemic parasite infection within 6 months before the Screening visit Any medical or psychiatric condition, laboratory, or ECG parameter which, in the opinion of the Investigator or the Sponsor's medical monitor, would place the subject at risk, interfere with participation in the study, or interfere with the interpretation of study results.

Sites / Locations

  • AkesoBio Investigative Site 2037, The First Affiliated Hospital of Bengbu Medical CollegeRecruiting
  • AkesoBio Investigative Site 2036, The First Affiliated Hospital of Wannan Medical CollegeRecruiting
  • AkesoBio Investigative Site 1001, Peking University People's HospitalRecruiting
  • AkesoBio Investigative Site 2044, Beijing Friendship Hospital, Capital Medical UniversityRecruiting
  • AkesoBio Investigative Site 2023, Xinqiao Hospital Medical UniversityRecruiting
  • AkesoBio Investigative Site 2024, Chongqing Three Gorges Medical CollegeRecruiting
  • AkesoBio Investigative Site 2040, Chongqing Traditional Chinese Medicine HospitalRecruiting
  • AkesoBio Investigative Site 2052, The First Affiliated Hospital of Chongqing Medical UniversityRecruiting
  • AkesoBio Investigative Site 2038, The First Affiliated Hospital of Fujian Medical UniversityRecruiting
  • AkesoBio Investigative Site 2022, Dongguan People's HospitalRecruiting
  • AkesoBio Investigative Site 1002, Guangdong Provincial People's HospitalRecruiting
  • AkesoBio Investigative Site 2003, Dermatology Hospital of Southern Medical UniversityRecruiting
  • AkesoBio Investigative Site 2049, The Affiliated Hospital of Guizhou Medical UniversityRecruiting
  • AkesoBio Investigative Site 2004, The First Affiliated Hospital of Hainan Medical UniversityRecruiting
  • AkesoBio Investigative Site 2001, Affiliated Hospital of Chengde medical universityRecruiting
  • AkesoBio Investigative Site 2010, Nanyang First People's Hospital National Third Class A HospitalRecruiting
  • AkesoBio Investigative Site 2051, Jingzhou Central HospitalRecruiting
  • AkesoBio Investigative Site 1005, Tongji Medical College, Huazhong University of Science and TechnologyRecruiting
  • AkesoBio Investigative Site 2046, The Third Xiangya Hospital of Central South UniversityRecruiting
  • AkesoBio Investigative Site 2008, The Affiliated Hospital of Inner Mongolia Medical UniversityRecruiting
  • AkesoBio Investigative Site 2048, The First People's Hospital of ChangzhouRecruiting
  • AkesoBio Investigative Site 2050, Wuxi Second People's HospitalRecruiting
  • AkesoBio Investigative Site 2025, Affiliated Hospital of Jiangsu UniversityRecruiting
  • AkesoBio Investigative Site 2032, The First Affiliated Hospital of Gannan Medical CollegeRecruiting
  • AkesoBio Investigative Site 2011, Northeast International HospitalRecruiting
  • AkesoBio Investigative Site 2039, Shandong Provincial Dermatology HospitalRecruiting
  • AkesoBio Investigative Site 2041, Qilu Hospital of Shandong UniversityRecruiting
  • AkesoBio Investigative Site 1003, Shanghai Skin Disease HospitalRecruiting
  • AkesoBio Investigative Site 2027, Medical School of Yanan UniversityRecruiting
  • AkesoBio Investigative Site 2029, West China Hospital，Sichuan UniversityRecruiting
  • AkesoBio Investigative Site 2034, Chengdu Second People's HospitalRecruiting
  • AkesoBio Investigative Site 2013, Tianjin Academy of Traditional Chinese Medicine Affiliated HospitalRecruiting
  • AkesoBio Investigative Site 2019, Tianjin Medical University General HospitalRecruiting
  • AkesoBio Investigative Site 2043, First Affiliated Hospital of Kunming Medical UniversityRecruiting
  • AkesoBio Investigative Site 1004, Zhejiang Provincial People's HospitalRecruiting
  • AkesoBio Investigative Site 2006,Affiliated Hangzhou First People's HospitalRecruiting
  • AkesoBio Investigative Site 2007, Hangzhou Third People's HospitalRecruiting
  • AkesoBio Investigative Site 2035, The Second Affiliated Hospital Zhejiang University School of MedicineRecruiting
  • AkesoBio Investigative Site 2009, The First Hospital of JiaxingRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm 10

Arm Type

Experimental

Experimental

Placebo Comparator

Experimental

Experimental

Experimental

Placebo Comparator

Experimental

Experimental

Experimental

Arm Label

AK120 150 mg in phase Ib

AK120 300mg in phase Ib

Placebo Comparator: Placebo in phase Ib

AK120 150mg in phase II

AK120 300mg in phase II

AK120 450mg in phase II

Placebo Comparator: Placebo in phase II

AK120 150mg in phase II extension

AK120 300mg in phase II extension

AK120 450mg in phase II extension

Arm Description

subcutaneous injection once a week for 4 weeks.

subcutaneous injection once a week for 4 weeks.

subcutaneous injection once a week for 4 weeks.

subcutaneous injection every 2 weeks for 50 weeks.

subcutaneous injection every 2 weeks for 50 weeks.

subcutaneous injection every 2 weeks for 50 weeks.

subcutaneous injection every 2 weeks, then crossover to AK120 Regimen 4 and Regimen 5, subcutaneous injection at week 16, after primary endpoint evaluation.

subcutaneous injection every 2 weeks for 14 weeks.

subcutaneous injection every 2 weeks for 14 weeks.

subcutaneous injection every 2 weeks for 14 weeks.

Outcomes

Primary Outcome Measures

Phase Ib
Incidence of treatment emergent AE . An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Phase Ib
T1/2 of AK120. Assessment of half-life(t1/2) of AK120.
Phase Ib
AUC of AK120. Assessment of Area under the curve(AUC) of AK120
Phase Ib
Cmax of AK120. Assessment of Peak concentration(Cmax) of AK120
Phase Ib
Tmax of AK120. Assessment of Time to peak(Tmax) of AK120
Phase II
Percentage of subjects who achieved (Eczema Area and Severity Index)EASI-75
Phase II Extension Study
Incidence of treatment emergent AE . An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.

Secondary Outcome Measures

Phase Ib
Percentage of subjects with detectable anti AK120 antibodies (ADA).
Phase Ib
Percentage of subjects who achieved 0/1 in the Investigator's Global Assessment (IGA)(on a 6-point scale) . Lower score of IGA mean better outcome, higher score mean worse outcome
Phase II
Percentage of subjects who achieved EASI-50 (≥50% improvement from baseline) /EASI-75 (≥75% improvement from baseline) response at each visit. Higher score mean better outcome, lower score mean worse outcome
Phase II
Percentage change in EASI scores from baseline at each visit. Higher score mean better outcome, lower score mean worse outcome
Phase II Extension Study
Percentage of subjects who achieved EASI-50 (≥50% improvement from baseline) /EASI-75 (≥75% improvement from baseline) response at each visit. Higher score mean better outcome, lower score mean worse outcome
Phase II Extension Study
Percentage change in EASI scores from baseline at each visit. Higher score mean better outcome, lower score mean worse outcome

Full Information

First Posted
June 2, 2023
Last Updated
September 6, 2023
Sponsor
Akeso
search

1. Study Identification

Unique Protocol Identification Number
NCT06035354
Brief Title
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic Dermatitis
Official Title
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in the Treatment of Subjects With Moderate to Severe Atopic Dermatitis
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 3, 2021 (Actual)
Primary Completion Date
September 30, 2024 (Anticipated)
Study Completion Date
October 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Akeso

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This is a randomized, double-blind, placebo-controlled, multicenter phase Ib/II clinical study to evaluate the safety, pharmacokinetics and efficacy of AK120 in the treatment of subjects with moderate to severe atopic dermatitis.
Detailed Description
This is a randomized, double-blind, placebo-controlled, multicenter phase Ib/II clinical study to evaluate the safety, pharmacokinetics and efficacy of AK120 in subjects with moderate to severe atopic dermatitis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atopic Dermatitis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation
Randomized
Enrollment
416 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
AK120 150 mg in phase Ib
Arm Type
Experimental
Arm Description
subcutaneous injection once a week for 4 weeks.
Arm Title
AK120 300mg in phase Ib
Arm Type
Experimental
Arm Description
subcutaneous injection once a week for 4 weeks.
Arm Title
Placebo Comparator: Placebo in phase Ib
Arm Type
Placebo Comparator
Arm Description
subcutaneous injection once a week for 4 weeks.
Arm Title
AK120 150mg in phase II
Arm Type
Experimental
Arm Description
subcutaneous injection every 2 weeks for 50 weeks.
Arm Title
AK120 300mg in phase II
Arm Type
Experimental
Arm Description
subcutaneous injection every 2 weeks for 50 weeks.
Arm Title
AK120 450mg in phase II
Arm Type
Experimental
Arm Description
subcutaneous injection every 2 weeks for 50 weeks.
Arm Title
Placebo Comparator: Placebo in phase II
Arm Type
Placebo Comparator
Arm Description
subcutaneous injection every 2 weeks, then crossover to AK120 Regimen 4 and Regimen 5, subcutaneous injection at week 16, after primary endpoint evaluation.
Arm Title
AK120 150mg in phase II extension
Arm Type
Experimental
Arm Description
subcutaneous injection every 2 weeks for 14 weeks.
Arm Title
AK120 300mg in phase II extension
Arm Type
Experimental
Arm Description
subcutaneous injection every 2 weeks for 14 weeks.
Arm Title
AK120 450mg in phase II extension
Arm Type
Experimental
Arm Description
subcutaneous injection every 2 weeks for 14 weeks.
Intervention Type
Drug
Intervention Name(s)
AK120
Intervention Description
subcutaneous injection once a week
Intervention Type
Drug
Intervention Name(s)
AK120
Intervention Description
subcutaneous injection once a week
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
subcutaneous injection once a week.
Intervention Type
Drug
Intervention Name(s)
AK120
Intervention Description
subcutaneous injection every 2 weeks.
Intervention Type
Drug
Intervention Name(s)
AK120
Intervention Description
subcutaneous injection every 2 weeks.
Intervention Type
Drug
Intervention Name(s)
AK120
Intervention Description
subcutaneous injection every 2 weeks.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
subcutaneous injection every 2 weeks for 16 weeks then crossover to AK120 Regimen 4 and Regimen 5.
Intervention Type
Drug
Intervention Name(s)
AK120
Intervention Description
subcutaneous injection every 2 weeks
Intervention Type
Drug
Intervention Name(s)
AK120
Intervention Description
subcutaneous injection every 2 weeks.
Intervention Type
Drug
Intervention Name(s)
AK120
Intervention Description
subcutaneous injection every 2 weeks.
Primary Outcome Measure Information:
Title
Phase Ib
Description
Incidence of treatment emergent AE . An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Time Frame
Baseline to week 12
Title
Phase Ib
Description
T1/2 of AK120. Assessment of half-life(t1/2) of AK120.
Time Frame
Baseline to week 12
Title
Phase Ib
Description
AUC of AK120. Assessment of Area under the curve(AUC) of AK120
Time Frame
Baseline to week 12
Title
Phase Ib
Description
Cmax of AK120. Assessment of Peak concentration(Cmax) of AK120
Time Frame
Baseline to week 12
Title
Phase Ib
Description
Tmax of AK120. Assessment of Time to peak(Tmax) of AK120
Time Frame
Baseline to week 12
Title
Phase II
Description
Percentage of subjects who achieved (Eczema Area and Severity Index)EASI-75
Time Frame
at week 16
Title
Phase II Extension Study
Description
Incidence of treatment emergent AE . An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Time Frame
Baseline to week 24
Secondary Outcome Measure Information:
Title
Phase Ib
Description
Percentage of subjects with detectable anti AK120 antibodies (ADA).
Time Frame
Baseline to week 12
Title
Phase Ib
Description
Percentage of subjects who achieved 0/1 in the Investigator's Global Assessment (IGA)(on a 6-point scale) . Lower score of IGA mean better outcome, higher score mean worse outcome
Time Frame
Baseline to week 12
Title
Phase II
Description
Percentage of subjects who achieved EASI-50 (≥50% improvement from baseline) /EASI-75 (≥75% improvement from baseline) response at each visit. Higher score mean better outcome, lower score mean worse outcome
Time Frame
Baseline to week 58
Title
Phase II
Description
Percentage change in EASI scores from baseline at each visit. Higher score mean better outcome, lower score mean worse outcome
Time Frame
Baseline to week 58
Title
Phase II Extension Study
Description
Percentage of subjects who achieved EASI-50 (≥50% improvement from baseline) /EASI-75 (≥75% improvement from baseline) response at each visit. Higher score mean better outcome, lower score mean worse outcome
Time Frame
Baseline to week 24
Title
Phase II Extension Study
Description
Percentage change in EASI scores from baseline at each visit. Higher score mean better outcome, lower score mean worse outcome
Time Frame
Baseline to week 24

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female with age 18 - 75 years (inclusive). Atopic dermatitis (AD) diagnosed at least half an year before screening. Subject with EASI score ≥16, IGA ≥ 3, BSA ≥ 10% at screening and baseline. Subjects with a history of an inadequate response or medically inappropriate use of topical drug treatment within 6 months. Exclusion Criteria: Suffering from other inflammatory diseases that may affect efficacy outcomes (such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, scleroderma, inflammatory myopathy, mixed connective tissue disease, overlap syndrome, etc.). History of exposure to active TB, and/or history or current evidence of TB infection. Positive serology results at Screening for hepatitis B, hepatitis C or HIV. Any history of vernal keratoconjunctivitis (VKC) or atopic keratoconjunctivitis (AKC) within 6 months before the baseline visit. History of clinical parasite infection, recent or planned travel to an area with endemic parasite infection within 6 months before the Screening visit Any medical or psychiatric condition, laboratory, or ECG parameter which, in the opinion of the Investigator or the Sponsor's medical monitor, would place the subject at risk, interfere with participation in the study, or interfere with the interpretation of study results.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Guoqin Wang
Phone
+86 (0760) 8987 3999
Email
global.trials@akesobio.com
Facility Information:
Facility Name
AkesoBio Investigative Site 2037, The First Affiliated Hospital of Bengbu Medical College
City
Bengbu
State/Province
Anhui
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 2036, The First Affiliated Hospital of Wannan Medical College
City
Wuhu
State/Province
Anhui
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 1001, Peking University People's Hospital
City
Beijing
State/Province
Beijing
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 2044, Beijing Friendship Hospital, Capital Medical University
City
Beijing
State/Province
Beijing
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 2023, Xinqiao Hospital Medical University
City
Chongqing
State/Province
Chongqing
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 2024, Chongqing Three Gorges Medical College
City
Chongqing
State/Province
Chongqing
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 2040, Chongqing Traditional Chinese Medicine Hospital
City
Chongqing
State/Province
Chongqing
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 2052, The First Affiliated Hospital of Chongqing Medical University
City
Chongqing
State/Province
Chongqing
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 2038, The First Affiliated Hospital of Fujian Medical University
City
Fuzhou
State/Province
Fujian
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 2022, Dongguan People's Hospital
City
Dongguan
State/Province
Guangdong
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 1002, Guangdong Provincial People's Hospital
City
Guangzhou
State/Province
Guangdong
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 2003, Dermatology Hospital of Southern Medical University
City
Guangzhou
State/Province
Guangdong
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 2049, The Affiliated Hospital of Guizhou Medical University
City
Guiyang
State/Province
Guizhou
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 2004, The First Affiliated Hospital of Hainan Medical University
City
Haikou
State/Province
Hainan
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 2001, Affiliated Hospital of Chengde medical university
City
Chengde
State/Province
Hebei
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 2010, Nanyang First People's Hospital National Third Class A Hospital
City
Nanyang
State/Province
Henan
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 2051, Jingzhou Central Hospital
City
Jingzhou
State/Province
Hubei
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 1005, Tongji Medical College, Huazhong University of Science and Technology
City
Wuhan
State/Province
Hubei
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 2046, The Third Xiangya Hospital of Central South University
City
Changsha
State/Province
Hunan
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 2008, The Affiliated Hospital of Inner Mongolia Medical University
City
Hohhot
State/Province
Inner Mongolia
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 2048, The First People's Hospital of Changzhou
City
Changzhou
State/Province
Jiangsu
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 2050, Wuxi Second People's Hospital
City
Wuxi
State/Province
Jiangsu
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 2025, Affiliated Hospital of Jiangsu University
City
Zhenjiang
State/Province
Jiangsu
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 2032, The First Affiliated Hospital of Gannan Medical College
City
Ganzhou
State/Province
Jiangxi
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 2011, Northeast International Hospital
City
Shenyang
State/Province
Liaoning
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 2039, Shandong Provincial Dermatology Hospital
City
Jinan
State/Province
Shandong
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 2041, Qilu Hospital of Shandong University
City
Jinan
State/Province
Shandong
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 1003, Shanghai Skin Disease Hospital
City
Shanghai
State/Province
Shanghai
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 2027, Medical School of Yanan University
City
Xianyang
State/Province
Shanxi
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 2029, West China Hospital，Sichuan University
City
Chengdu
State/Province
Sichuan
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 2034, Chengdu Second People's Hospital
City
Chengdu
State/Province
Sichuan
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 2013, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
City
Tianjin
State/Province
Tianjin
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 2019, Tianjin Medical University General Hospital
City
Tianjin
State/Province
Tianjin
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 2043, First Affiliated Hospital of Kunming Medical University
City
Kunming
State/Province
Yunnan
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 1004, Zhejiang Provincial People's Hospital
City
Hangzhou
State/Province
Zhejiang
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 2006,Affiliated Hangzhou First People's Hospital
City
Hangzhou
State/Province
Zhejiang
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 2007, Hangzhou Third People's Hospital
City
Hangzhou
State/Province
Zhejiang
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 2035, The Second Affiliated Hospital Zhejiang University School of Medicine
City
Hangzhou
State/Province
Zhejiang
Country
China
Individual Site Status
Recruiting
Facility Name
AkesoBio Investigative Site 2009, The First Hospital of Jiaxing
City
Jiaxing
State/Province
Zhejiang
Country
China
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic Dermatitis

We'll reach out to this number within 24 hrs